For the Inventor, By the Inventor

Enter assignee name

Berkshire, United Kingdom

Zogenix International Limited

USPTO Granted Patents = 22

% Expired Patents = 9.1

EPO Patents = 8

Trademarks = 2

Forward Citations = 155

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Brooks M Boyd (10 out of 17 patents)

Stephen J Farr (8 out of 32 patents)

Bradley S Galer (5 out of 18 patents)

4. Marc W Andersen (4 out of 14 patents)

5. Derek John Londesbrough (4 out of 11 patents)

6. Parthena Martin (3 out of 3 patents)

7. Carl L Faingold (2 out of 2 patents)

8. Richard Alistair Balfour Stewart (2 out of 3 patents)

9. Anthony Clarke (2 out of 8 patents)

10. Khawla Abu-Izza (2 out of 2 patents)

11. David Hickman (2 out of 2 patents)

12. Glenn Arthur Morrison (2 out of 9 patents)

13. Stephan J Farr (1 out of 1 patent)

14. Bret Megargel (1 out of 1 patent)

15. Brooks Boyd (4 patents)

22 patents: Sort by Forward Citations

1. 12734137 - Methods of treating Lennox-Gastaut Syndrome using fenfluramine (2026-09-15),

2. 12144787 - Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) (2024-11-19),

3. 11786487 - Formulation for inhibiting formation of 5-HTagonists and methods of using same (2023-10-17),

4. 11759440 - Formulation for inhibiting formation of 5-HTagonists and methods of using same (2023-09-19),

5. 11673852 - Metabolism resistant fenfluramine analogs and methods of using the same (2023-06-13),

6. 11634377 - Fenfluramine compositions and methods of preparing the same (2023-04-25),

7. 11612574 - Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2023-03-28),

8. 11571397 - Compositions and methods for treating seizure-induced sudden death (2023-02-07),

9. 11458111 - Ketogenic diet compatible fenfluramine formulation (2022-10-04),

10. 11406606 - Formulation for inhibiting formation of 5-HT2B agonists and methods of using same (2022-08-09),

11. 11325882 - Metabolism resistant fenfluramine analogs and methods of using the same (2022-05-10),

12. 11040018 - Formulation for inhibiting formation of 5-HT2B agonists and methods of using same (2021-06-22),

13. 10952976 - Compositions and methods for treating respiratory depression with fenfluramine (2021-03-23),

14. 10950331 - Control system for control of distribution of medication (2021-03-16),

15. 10947183 - Fenfluramine compositions and methods of preparing the same (2021-03-16),

Company Overview

Zogenix International Limited is a biopharmaceutical company based in Berkshire, UK, focusing on the development of innovative therapies for patients with rare neurological diseases. The organization specializes in advanced drug delivery systems and has a strong emphasis on addressing unmet medical needs through its research and development efforts. Zogenix is committed to improving patient outcomes by leveraging cutting-edge technology and scientific expertise in the field of neurology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

22 Patents

#9 in Berkshire

#814 in United Kingdom

#28,782 in the World

Berkshire, United Kingdom

Zogenix International Limited

Forward Citations = 155

16 inventors:

Brooks M Boyd (10 out of 17 patents)

Stephen J Farr (8 out of 32 patents)

Bradley S Galer (5 out of 18 patents)

4. Marc W Andersen (4 out of 14 patents)

5. Derek John Londesbrough (4 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zogenix International Limited. Retrieved from https://idiyas.com/company/zogenix-international

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…